Having completed a Phase I/Iia study of Ovasave, a drug candidate from its first generation non-modified antigen-specific regulatory T-cells (Tregs), TxCell expects to start a first in man study of a candidate from its next generation Treg platform in 2018. The company switched emphasis from its ASTrIA platform to the ENTrIA platform two years ago after coming up against some manufacturing issues.
TxCell Plans First In Man Trial Of Regulatory T-Cells
Stéphane Boissel, CEO of TxCell, discusses the company's plans to advance its lead next-generation regulatory T-cell candidate into human studies, after having switched to a new platform, in a video interview with Scrip.
More from R&D
• By
With the FDA asking for another Phase III trial, the short bowel syndrome drug apraglutide could be years away from market, while the Linzess patent expiry and near-term debt loom.
• By
The company discontinued development of its oral GLP-1 receptor agonist for weight management due to a safety signal.
• By
The bispecific is the first in its class to record a Phase III survival win in small-cell lung cancer, although antibody-drug conjugates and other rivals could challenge in the coming years.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
More from Scrip
• By
The bispecific is the first in its class to record a Phase III survival win in small-cell lung cancer, although antibody-drug conjugates and other rivals could challenge in the coming years.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
• By
The Oxford group has linked up with the NHS Cancer Vaccine Launch Pad.